EUVIMEDEUVIMED entdecken
Crossref

Continuous Processing for Manufacturing of Antibody–Drug Conjugates (ADCs)

Subhankar Metya, Pragya Prakash, Anurag S Rathore iD

Bioconjugate Chemistry · 18.02.2026 · 37 (2) · 395-405

DOI: 10.1021/acs.bioconjchem.5c00599 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioconjugate Chemistry, online erschienen am 02.02.2026. Verfasst von Subhankar Metya und 2 weiteren Autor:innen. Beteiligte Einrichtung: School of Interdisciplinary Research, Indian Institute of Technology Delhi, New Delhi 110016, India. Hauptthemen laut MEDLINE: Immunoconjugates, Antibodies, Monoclonal. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: Department of Biotechnology, Ministry of Science and Technology, India.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibody-drug conjugates (ADCs) are a promising and emerging class of biotherapeutics that combine the targeting precision of monoclonal antibodies (mAbs) with the cytotoxic potency of small-molecule drugs. Their manufacturing, however, requires conjugation of the mAb with the pertinent small molecule drug, a step typically is inefficient, incurring wastage of both the mAb and the drug. In addition, ADC manufacturing is challenged by precise control of drug-to-antibody ratio (DAR), aggregation, safe handling of cytotoxic payloads, among other factors. In this work, we present a novel approach for continuous conjugation of the mAb and the drug, by utilizing a coiled flow inverter reactor (CFIR) to facilitate the thiol-maleimide conjugation at interchain cysteines residues in the mAb. As an initial step, the process parameters for reducing thiol groups and the conjugation steps were screened, followed by optimization of the significant parameters (concentration of mAb and drug/linker payload, reaction duration, and temperature) using design of experiments (DoE) methodology. The performance of the CFIR was then compared to that of traditional batch conjugation. We demonstrate that the CFIR offers 64.40% higher productivity, 70% lower cost of production, and a safer alternative to the traditional batch conjugation, while producing clinically relevant DAR. This work illustrates the potential of continuous processing to transform ADC manufacturing by enabling more efficient, scalable, and sustainable production platforms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunoconjugatesAntibodies, MonoclonalMaleimidesSulfhydryl CompoundsContinuous Flow ChemistryHumansCysteine

Substanzen

ImmunoconjugatesAntibodies, MonoclonalMaleimidesSulfhydryl CompoundsmaleimideCysteine

Autor:innen und Institutionen

  • School of Interdisciplinary Research, Indian Institute of Technology Delhi, New Delhi 110016, India.
  • Department of Chemical Engineering, Indian Institute of Technology Delhi, New Delhi 110016, India.

ORCID-Profile: Anurag S Rathore

Förderung

  • Department of Biotechnology, Ministry of Science and Technology, India

Zitieren

APA

Metya, S., Prakash, P., & Rathore, A. S. (2026). Continuous Processing for Manufacturing of Antibody–Drug Conjugates (ADCs). Bioconjugate Chemistry, 37(2), 395-405. https://doi.org/10.1021/acs.bioconjchem.5c00599

Vancouver

Metya S, Prakash P, Rathore AS. Continuous Processing for Manufacturing of Antibody–Drug Conjugates (ADCs). Bioconjugate Chemistry. 2026;37(2):395-405. doi:10.1021/acs.bioconjchem.5c00599

BibTeX
@article{Metya2026,
  author = {Metya, Subhankar and Prakash, Pragya and Rathore, Anurag S},
  title = {Continuous Processing for Manufacturing of Antibody–Drug Conjugates (ADCs)},
  journal = {Bioconjugate Chemistry},
  year = {2026},
  volume = {37},
  number = {2},
  pages = {395--405},
  doi = {10.1021/acs.bioconjchem.5c00599}
}
Kostenlos starten →